To improve the quality of life for people with haemophilia in Europe:
- Approximately 80,000 people in Europe have been diagnosed with haemophilia.
We work to:
- improve diagnostic and treatment facilities - because up to 50% of haemophilia patients in Europe receive inadequate care.
- ensure adequate supply of safe factor concentrates - because more than 50% of factor concentrates used in Europe derives from human plasma. Many persons with haemophilia were infected with life threatening viruses such as HIV and Hepatitis C as a result of their treatment in the seventies and early 1980ies.
- promote patients’ rights and raise ethical issues - because minority groups need well established organisations to take care of their interests.
- follow and influence developments in European Health Policy because a number of the European Health Policies affect persons with haemophilia in Europe and worldwide.
- undertake surveys of the status of haemophilia care in member countries because statistical material is essential for monitoring national developments and establishing of national haemophilia programs.
- stimulate research in all fields related to haemophilia because developments in biotechnology are of extreme importance to future haemophilia treatment.
